Krystal BiotechNASDAQ: KRYS

PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim Securities Healthcare Innovation Conference on November 12, 2024, in Boston. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:30 pm ET and host investor meetings throughout the day.

KRYS beat on both earnings and sales in the third quarter of 2024. Lead drug Vyjuvek's launch in the United States shows strong uptake.

PITTSBURGH, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its third quarter 2024 financial results on Monday, November 4, 2024, prior to the open of U.S. markets.

Krystal Biotech (KRYS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The company anticipates significant Q4 2024 data releases for KB707 in solid tumors and KB408 in AATD lung disease, potentially boosting shareholder value. Jeune Therapeutics, a subsidiary, shows promise in aesthetics with positive phase 1 data, changing the treatment paradigm in the aesthetics market space. VYJUVEK, approved for DEB, saw a 55.3% revenue increase in Q2 2024, with potential European expansion pending MAA approval.

Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

KRYS has gained 21.9% in the past three months on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.

Krystal Biotech, Inc. (NASDAQ:KRYS ) Q2 2024 Earnings Conference Call August 5, 2024 8:30 AM ET Company Participants Stéphane Paquette - Vice President, Corporate Development Krish Krishnan - Chairman and CEO Suma Krishnan - President, Research and Development Jennifer McDonough - Senior Vice President, Patient Access, Analytics and Operations Christine Wilson - Senior Vice President and Head, U.S. Sales and Marketing Kate Romano - Chief Accounting Officer Conference Call Participants Alec Stranahan - Bank of America Ritu Baral - TD Cowen Andrea Tan - Goldman Sachs John Boyle - William Blair Yigal Nochomovitz - Citi Gavin Clark Gartner - Evercore ISI Dae Gon Ha - Stifel Debjit Chattopadhyay - Guggenheim Securities Operator Thank you for standing by. And welcome to Krystal Biotech's Second-Quarter 2024 Earnings Conference Call.

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.50 per share. This compares to loss of $1.25 per share a year ago.